Metformin in reproductive health, pregnancy and gynaecological cancer: established and emerging indications
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Metformin is an effective oral anti-hyperglycaemic drug used as first-line medical treatment for type 2 diabetes. It improves systemic hyperglycaemia by reducing hepatic glucose production and enhancing peripheral insulin sensitivity. It also stimulates fat oxidation and reduces fat synthesis and storage. The molecular mechanism of this drug is thought to be secondary to its actions on the mitochondrial respiratory chain. METHODS: This paper reviews the relevant literature (research articles up to October 2013) on the use of metformin in infertility, polycystic ovary syndrome (PCOS), pregnancy and gynaecological cancers. We present a comprehensive discussion of the evidence supporting the efficacy of metformin in these clinical conditions. RESULTS: Metformin is used clinically off-label in the management of hirsutism, acne and insulin resistance in PCOS, although the evidence for anti-androgenic effects is inconsistent. Metformin is also used to improve ovulation in women with PCOS both alone and in combination with clomiphene citrate. Trial findings are conflicting but metformin treatment in IVF/ICSI cycles may reduce the risk of ovarian hyperstimulation syndrome and increase live birth rates. Metformin also appears to be effective and safe for the treatment of gestational diabetes mellitus (GDM), particularly for overweight and obese women. Studies have shown that metformin is safe in pregnancy and women with GDM treated with metformin have less weight gain during pregnancy than those treated with insulin. One study with a 2-year follow-up demonstrated that babies born to women treated with metformin also developed less visceral fat, making them less prone to insulin resistance in later life. These findings have sparked interest in the use of metformin for pregnant, obese, non-diabetic women. On-going clinical trials are underway to determine if women treated prophylactically with metformin have a reduced incidence of GDM and demonstrate less weight gain during pregnancy. The hypothesis in these studies is that babies born to obese women on prophylactic metformin will also have better outcomes. Epidemiological studies have linked metformin exposure to a decreased risk of cancer. Pre-clinical experiments report that metformin has a growth-static effect on several cancers, including endometrial cancer, which may be partly due to the effect of metformin on the PI3K/AKT/mTOR signal transduction pathway. A number of on-going early phase clinical trials aim to explore the anti-cancer effects of metformin and investigate its potential as a chemopreventative or adjuvant treatment. CONCLUSIONS: Obesity is on the rise in developing countries and is strongly linked to several reproductive health problems, including PCOS, GDM and endometrial cancer. Traditional lifestyle measures aimed at weight reduction are challenging to implement and maintain. Metformin may be a valuable alternative to, or adjunct for, modifying the toxic effects of obesity in these populations. This review will appraise the evidence for the use of metformin for the prevention and treatment of adverse health outcomes in obstetrics and gynaecology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 1×
“…in patients with impaired glucose tolerance by as much as 31% (95% confidence interval (CI) 17 –43) when compared with placebo, although lifestyle interventions that achieve weight loss and regular exercise are even more effective (58% reduction in risk, 95% CI 48– 66) (Knowler et al., 2002).”
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Renehan, A. G., Tyson, M., Egger, M., Heller, R. F., & Zwahlen, M. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60269-x · Cited by 5,219
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919 · cited 1×
“Metformin is the preferred and most cost-effective first-line oral therapy for the treatment of T2DM (Nathan et al., 2009; Inzucchi et al., 2012) and is usually well tolerated and not complicated by hypoglycaemia .”
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388 · cited 1×
“A flurry of prospective observational studies suggested that patients with T2DM taking metformin were not only at lower risk of developing cancer (Libby et al., 2009) but were also less likely to die from it (Evans et al., 2005).”
OWEN, M. R., DORAN, E., & HALESTRAP, A. P. (2000) · Biochemical Journal · doi:10.1042/bj3480607 · Cited by 2,157 · cited 1×
“Metformin inhibits the mitochondrial respiratory complex I (El-Mir et al., 2000; Owen et al., 2000), leading to reduced oxidative phosphorylation and ATP production.”
Insulin and insulin-like growth factor signalling in neoplasia
Pollak, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2536 · Cited by 2,059 · cited 1×
“3) (Pollak, 2008).”
Fauser, B. C. J. M., Tarlatzis, B. C., Rebar, R. W., Legro, R. S., Balen, A. H., Lobo, R., Carmina, E., Chang, J., Yildiz, B. O., Laven, J. S. E., et al. (2012) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.09.024 · Cited by 1,976 · cited 1×
“Cardiovascular risk factors for ischaemic heart disease and stroke include obesity, insulin resistance, glucose intolerance, diabetes, hypertension, dyslipidemia (in particular raised serum triglycerides) and various markers of inflammation (Fauser et al., 2012).”
Self-citationRamachandran, A., Snehalatha, C., Mary, S., Mukesh, B., Bhaskar, A. D., Vijay, V., & Indian Diabetes Prevention Programme (IDPP) (2006) · Diabetologia · doi:10.1007/s00125-005-0097-z · Cited by 1,881
The Mitochondrial Carnitine Palmitoyltransferase System — From Concept to Molecular Analysis
McGarry, J. D., & Brown, N. F. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.00001.x · Cited by 1,616 · cited 1×
“Its activation by metformin decreases lipid synthesis, increases fatty acid oxidation and inhibits gluconeogenesis (McGarry and Brown, 1997; Li et al., 2011).”
Cited by
Pregnancy complications in women with polycystic ovary syndrome
Palomba, S., de Wilde, M. A., Falbo, A., Koster, M. P. H., La Sala, G. B., & Fauser, B. C. J. M. (2015) · Human Reproduction Update · doi:10.1093/humupd/dmv029 · Cited by 691
“Potential advantages for the use of metformin over insulin in GDM were suggested regarding maternal weight gain during pregnancy, neonatal outcomes (including less visceral fat) and patient compliance (Rowan et al., 2008; Lautatzis et al., 2013; Sivalingam et al., 2014).”
BackgroundP53 coordinates decidual sestrin 2/AMPK/mTORC1 signaling to govern parturition timing
Deng, W., Cha, J., Yuan, J., Haraguchi, H., Bartos, A., Leishman, E., Viollet, B., Bradshaw, H. B., Hirota, Y., & Dey, S. K. (2016) · Journal of Clinical Investigation · doi:10.1172/jci87715 · Cited by 85
Fornes, R., Simin, J., Nguyen, M. H., Cruz, G., Crisosto, N., van der Schaaf, M., Engstrand, L., & Brusselaers, N. (2022) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-022-00905-6 · Cited by 44
Metadata
- Authors
- Sivalingam, V. N., Myers, J., Nicholas, S., Balen, A. H., & Crosbie, E. J.
- Venue
- Human Reproduction Update
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-07-10
- Volume
- 20
- Issue
- 6
- Pages
- 853-868
- ISSN
- 1355-4786 (ISSN-L)
- 1460-2369
- OpenAlex
- W2161384735
- Cited by
- 108
- References
- 54
- FWCI
- 4.87
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metformin in reproductive health, pregnancy and gynaecological cancer: established and emerging indications. https://app.cochat.ai/papers/10.1093/humupd/dmu037
- The paper
- Sivalingam, V. N., Myers, J., Nicholas, S., Balen, A. H., & Crosbie, E. J. (2014). Metformin in reproductive health, pregnancy and gynaecological cancer: established and emerging indications. Human Reproduction Update. https://doi.org/10.1093/humupd/dmu037
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.